NDAINTRAVENOUSINJECTABLE
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INFUVITE PEDIATRIC (multiple vitamins injection) by Novartis. Approved for vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition (). First approved in 2001.
Drug data last refreshed 5h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INFUVITE PEDIATRIC is a multiple vitamins injection administered intravenously to prevent vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. This product provides essential vitamins to support normal metabolic function and development in children unable to obtain nutrition orally. The formulation contains Vitamin C as its primary active component among a spectrum of essential vitamins.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential restructuring and downsizing of commercial teams within the next 2-3 years.
Mechanism of Action
Pharmacologic Class:
Vitamin C
Career Relevance
Working on INFUVITE PEDIATRIC offers limited career growth opportunities given its mature, niche market position and approaching loss of exclusivity. Career progression is primarily available in manufacturing operations and R&D process optimization roles rather than commercial or medical advancement.
Worked on INFUVITE PEDIATRIC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.